Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.

IF 2.9 3区 医学 Q2 ONCOLOGY
Expert Review of Anticancer Therapy Pub Date : 2024-06-01 Epub Date: 2024-05-26 DOI:10.1080/14737140.2024.2344647
Paola Tacchetti, Marco Talarico, Simona Barbato, Lucia Pantani, Katia Mancuso, Ilaria Rizzello, Elena Zamagni, Michele Cavo
{"title":"Antibody-drug conjugates, bispecific antibodies and CAR-T cells therapy in multiple myeloma.","authors":"Paola Tacchetti, Marco Talarico, Simona Barbato, Lucia Pantani, Katia Mancuso, Ilaria Rizzello, Elena Zamagni, Michele Cavo","doi":"10.1080/14737140.2024.2344647","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Modern immunotherapy approaches are revolutionizing the treatment scenario of relapsed/refractory (RR) multiple myeloma (MM) patients, providing an opportunity to reach deep level of responses and extend survival outcomes.</p><p><strong>Areas covered: </strong>Antibody-drug conjugates (ADCs) and T-cell redirecting treatments, including bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T cells therapy, have been recently introduced in the treatment of RRMM. Some agents have already received regulatory approval, while newer constructs, novel combinations, and applications in earlier lines of therapy are currently being explored. This review discusses the current landscape and possible development of ADCs, BsAbs and CAR-T cells immunotherapies.</p><p><strong>Expert opinion: </strong>ADCs, BsAbs, and CAR-T therapy have demonstrated substantial activity in heavily pretreated, triple-class exposed (TCE) MM patients, and T-cell redirecting treatments represent new standards of care after third (European Medicines Agency, EMA), or fourth (Food and Drug Administration, FDA), line of therapy. All these three immunotherapies carry advantages and disadvantages, with different accessibility and new toxicities that require appropriate management and guidelines. Multiple on-going programs include combinations therapies and applications in earlier lines of treatment, as well as the development of novel agents or construct to enhance potency, reduce toxicity and facilitate administration. Sequencing is a challenge, with few data available and mechanisms of resistance still to be unraveled.</p>","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":null,"pages":null},"PeriodicalIF":2.9000,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2344647","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Modern immunotherapy approaches are revolutionizing the treatment scenario of relapsed/refractory (RR) multiple myeloma (MM) patients, providing an opportunity to reach deep level of responses and extend survival outcomes.

Areas covered: Antibody-drug conjugates (ADCs) and T-cell redirecting treatments, including bispecific antibodies (BsAbs) and chimeric antigen receptor (CAR) T cells therapy, have been recently introduced in the treatment of RRMM. Some agents have already received regulatory approval, while newer constructs, novel combinations, and applications in earlier lines of therapy are currently being explored. This review discusses the current landscape and possible development of ADCs, BsAbs and CAR-T cells immunotherapies.

Expert opinion: ADCs, BsAbs, and CAR-T therapy have demonstrated substantial activity in heavily pretreated, triple-class exposed (TCE) MM patients, and T-cell redirecting treatments represent new standards of care after third (European Medicines Agency, EMA), or fourth (Food and Drug Administration, FDA), line of therapy. All these three immunotherapies carry advantages and disadvantages, with different accessibility and new toxicities that require appropriate management and guidelines. Multiple on-going programs include combinations therapies and applications in earlier lines of treatment, as well as the development of novel agents or construct to enhance potency, reduce toxicity and facilitate administration. Sequencing is a challenge, with few data available and mechanisms of resistance still to be unraveled.

多发性骨髓瘤的抗体药物共轭物、双特异性抗体和 CAR-T 细胞疗法。
简介:现代免疫疗法正在彻底改变复发/难治性(RR)多发性骨髓瘤(MM)患者的治疗方案,为达到深层次应答和延长生存期提供了机会:抗体药物共轭物(ADC)和T细胞重定向疗法,包括双特异性抗体(BsAbs)和嵌合抗原受体(CAR)T细胞疗法,最近已被引入RRMM的治疗中。一些药物已获得监管部门的批准,而更新的构建物、新型组合以及在早期疗法中的应用目前正在探索之中。本综述讨论了ADCs、BsAbs和CAR-T细胞免疫疗法的现状和可能发展:ADCs、BsAbs和CAR-T疗法已在接受重度预处理、三类暴露(TCE)的MM患者中显示出巨大的活性,T细胞重定向疗法代表了第三(欧洲药品管理局,EMA)或第四(美国食品和药物管理局,FDA)线治疗后的新治疗标准。这三种免疫疗法各有利弊,具有不同的可及性和新的毒性,需要适当的管理和指导。目前正在进行的多个项目包括联合疗法和早期治疗方法的应用,以及新型制剂或构建物的开发,以提高效力、降低毒性和方便给药。测序是一项挑战,目前可用的数据很少,抗药性机制仍有待揭示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.10
自引率
3.00%
发文量
100
审稿时长
4-8 weeks
期刊介绍: Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信